Bluebird Bio could raise $86.25 million via public stock offering

J.P. Morgan Securities, BofA Merrill Lynch help raise funds for R&D

By Toni Weeks

San Luis Obispo, Calif., May 14 - Bluebird Bio, Inc. said it will price its initial public offering of stock to raise up to $86.25 million, according to a form S-1 filing with the Securities and Exchange Commission. There will be a 30-day greenshoe to cover over-allotments.

J.P. Morgan Securities LLC and BofA Merrill Lynch are the joint bookrunning managers. Cowen and Co., Canaccord Genuity and Wedbush PacGrow Life Sciences are additional underwriters.

Proceeds will be used for research and development expenses and general and administrative expenses.

The clinical-stage biopharmaceutical company is developing and commercializing products that use gene therapy to treat patients with severe genetic and orphan diseases. It is based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.